A recent report from health insurance data non-profit organisation FAIR Health suggested that more than 2% of adult Americans are using GLP-1 therapies for obesity or those who are overweight, approximately 5 million people
Archives of Toxicology 0
H., Puspitarum, L., Sujitno, T., Suprihatin, H., Purwanto, S., & Suharyadi, E
Through the control of the Fenton reaction, iron chelators such as deferoxamine chelate iron and halt lipid peroxidation
The most frequently reported symptoms include: Nausea (especially during dose increases) Vomiting Diarrhea Constipation Abdominal discomfort Decreased appetite (an expected effect of the medication) For most patients, side effects stay in the tolerable range and tend to taper off as treatment continues